Learn about Novartis annual results, including media releases, annual reports, webcasts and presentations, and year-to-date figures.
The Novartis in Society Integrated Report provides an overview our business, strategy and performance, and describes how we create sustainable value for stakeholders and society. Annual Report 2024 The Annual Report 2024, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overv...
This statistic was assembled from several editions of Novartis' annual report. * With the 2015 Annual Report, values back to 2011 were restated, as a result of a series of transactions during 2015. ** During this year, eye care division Alcon was spun off and became an own company. Thus...
Novartis in Society Integrated Report 2023 Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society. View the online summary Welcome to where we thrive together Working together. Learning together. Thriving together. Discover how...
Novartis' latest annual report shows a drop in sales of the drug in 2020. Colorado Biosciences Association Vice President Emily Roberts noted that the trade group does not believe Novartis' departure will undermine the industry's momentum in the state. She pointed to large operators such as ...
Ratings by Access to Medicine Index, CDP, MSCI, Sustainalytics and ISS ESG. ESG targets We aim to improve equity in healthcare and to create sustainable social and environmental impact. Living wage We are committed to paying employees wages that cover basic living needs. ...
We're annualizing now well above $3 billion, and have the opportunity, I think, to well exceed our $4 billion peak sales guidance to date. To our knowledge, there are no Kesimpta biosimilars currently in clinical development, which should give us a long runway looking forward for this medi...
Novartis AG (NVS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc....
Annual Report for 2017, which was furnished to the SEC on Form 6-K on January 24, 2018 and incorporated by reference into Novartis AG's Annual Report on Form 20-F for the fiscal year ended December 31, 2017. Information about the dire...
1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 47 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Relea...